CN110234638B - 杂芳基苯氧基苯甲酰胺kappa阿片类配体 - Google Patents

杂芳基苯氧基苯甲酰胺kappa阿片类配体 Download PDF

Info

Publication number
CN110234638B
CN110234638B CN201780084763.0A CN201780084763A CN110234638B CN 110234638 B CN110234638 B CN 110234638B CN 201780084763 A CN201780084763 A CN 201780084763A CN 110234638 B CN110234638 B CN 110234638B
Authority
CN
China
Prior art keywords
methyl
pyrazol
pyrrolidin
phenoxy
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780084763.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110234638A (zh
Inventor
K·K·阿罗拉
M·A·布罗德尼
M·F·邓恩
M·E·格林
N·M·卡布劳乌伊
G·W·考夫曼
S·R·门特
J·I·蒙哥马利
D·A·兰基奇
B·N·罗杰斯
P·R·费尔赫斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN110234638A publication Critical patent/CN110234638A/zh
Application granted granted Critical
Publication of CN110234638B publication Critical patent/CN110234638B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780084763.0A 2016-11-28 2017-11-27 杂芳基苯氧基苯甲酰胺kappa阿片类配体 Active CN110234638B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662426980P 2016-11-28 2016-11-28
US62/426,980 2016-11-28
US201762576435P 2017-10-24 2017-10-24
US62/576,435 2017-10-24
US201762585016P 2017-11-13 2017-11-13
US62/585,016 2017-11-13
PCT/IB2017/057418 WO2018096510A1 (en) 2016-11-28 2017-11-27 Heteroarylphenoxy benzamide kappa opioid ligands

Publications (2)

Publication Number Publication Date
CN110234638A CN110234638A (zh) 2019-09-13
CN110234638B true CN110234638B (zh) 2022-10-21

Family

ID=60782279

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780084763.0A Active CN110234638B (zh) 2016-11-28 2017-11-27 杂芳基苯氧基苯甲酰胺kappa阿片类配体

Country Status (18)

Country Link
US (1) US10316021B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544972B8 (cg-RX-API-DMAC7.html)
JP (1) JP7051853B2 (cg-RX-API-DMAC7.html)
CN (1) CN110234638B (cg-RX-API-DMAC7.html)
AU (1) AU2017365123B2 (cg-RX-API-DMAC7.html)
DK (1) DK3544972T3 (cg-RX-API-DMAC7.html)
ES (1) ES2947293T3 (cg-RX-API-DMAC7.html)
FI (1) FI3544972T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230518T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061945T2 (cg-RX-API-DMAC7.html)
IL (1) IL266962B (cg-RX-API-DMAC7.html)
MX (1) MX389806B (cg-RX-API-DMAC7.html)
PH (1) PH12019501172A1 (cg-RX-API-DMAC7.html)
PL (1) PL3544972T3 (cg-RX-API-DMAC7.html)
PT (1) PT3544972T (cg-RX-API-DMAC7.html)
RS (1) RS64258B1 (cg-RX-API-DMAC7.html)
TW (1) TWI720272B (cg-RX-API-DMAC7.html)
WO (1) WO2018096510A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018154118A2 (en) * 2017-02-24 2018-08-30 Reinmueller Viktoria Novel aromatic compounds
AU2018223177B2 (en) * 2017-02-24 2024-05-02 Xeniopro GmbH Aromatic compounds which enhance notch signaling, for use in therapy
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
MX2021013934A (es) * 2020-04-05 2021-12-15 Pfizer Compuestos y metodos para el tratamiento de covid-19.
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
EP4489748A1 (en) * 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
CN119156211A (zh) * 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
US20250353832A1 (en) * 2022-10-12 2025-11-20 Adama Makhteshim Ltd. Process for the preparation of aminopyridazine derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6420415B1 (en) 1998-09-21 2002-07-16 Takeda Chemical Industries, Ltd. Thiol compounds, their production and use
JP2000159747A (ja) 1998-09-21 2000-06-13 Takeda Chem Ind Ltd 新規チオ―ル誘導体、その製造法および用途
IT1303737B1 (it) 1998-11-11 2001-02-23 Smithkline Beecham Spa Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1.
PT2208727E (pt) 2002-09-19 2012-10-11 Lilly Co Eli Éteres diarílicos como antagonista do receptor opióide
US7365209B2 (en) 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
EP1606275B1 (en) 2003-03-07 2008-08-27 Eli Lilly And Company Opioid receptor antagonists
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US8188277B2 (en) 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
EP1849835B1 (en) 2005-02-18 2017-08-30 Nippon Soda Co., Ltd. Organic-inorganic composite body
RU2008140144A (ru) 2006-03-10 2010-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента
PL2001456T3 (pl) 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
US7709522B2 (en) 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
CR11559A (es) 2008-03-25 2010-10-20 Lilly Co Eli Antagonista del receptor opioide selectivo kappa
US8048895B2 (en) 2008-04-18 2011-11-01 Research Triangle Institute Kappa opioid receptor ligands
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
EP2379524A1 (en) 2008-12-18 2011-10-26 Boehringer Ingelheim International GmbH Serotonin 5-ht2b receptor inhibitors
HN2010001319A (es) 2009-01-26 2013-01-15 Lilly Co Eli Antagonista del receptor opioide selectivo kappa
WO2013059648A1 (en) 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use
EP2903966A1 (en) 2012-10-02 2015-08-12 Merck Patent GmbH Pyrrolidines
WO2015109080A1 (en) 2014-01-15 2015-07-23 Research Triangle Institute Kappa-opioid receptor selective opioid receptor antagonists
US10118896B2 (en) 2014-11-26 2018-11-06 University Of Kansas Antagonists of the kappa opioid receptor

Also Published As

Publication number Publication date
US20180148432A1 (en) 2018-05-31
TW201831460A (zh) 2018-09-01
TWI720272B (zh) 2021-03-01
EP3544972B8 (en) 2023-06-07
EP3544972B1 (en) 2023-04-26
AU2017365123B2 (en) 2022-02-17
ES2947293T3 (es) 2023-08-04
JP7051853B2 (ja) 2022-04-11
JP2019535799A (ja) 2019-12-12
MX2019006220A (es) 2019-10-07
RS64258B1 (sr) 2023-07-31
CN110234638A (zh) 2019-09-13
MX389806B (es) 2025-03-20
US10316021B2 (en) 2019-06-11
IL266962A (en) 2019-07-31
FI3544972T3 (fi) 2023-06-02
CA3045242A1 (en) 2018-05-31
NZ754862A (en) 2024-11-29
IL266962B (en) 2022-02-01
PH12019501172A1 (en) 2019-12-11
AU2017365123A1 (en) 2019-07-11
DK3544972T3 (da) 2023-05-30
PL3544972T3 (pl) 2023-07-24
PT3544972T (pt) 2023-06-20
HUE061945T2 (hu) 2023-09-28
HRP20230518T1 (hr) 2023-08-04
WO2018096510A1 (en) 2018-05-31
EP3544972A1 (en) 2019-10-02

Similar Documents

Publication Publication Date Title
TWI720272B (zh) 雜芳基苯氧基苯甲醯胺kappa類鴉片配體
US10858373B2 (en) Heterocyclic spiro compounds as MAGL inhibitors
JP7446348B2 (ja) テトラヒドロ-ピリド[3,4-b]インドールエストロゲン受容体モジュレーター及びその使用
CA3118330A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
EA035823B1 (ru) 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
CA3045816A1 (en) Oga inhibitor compounds
US20240408064A1 (en) Ras inhibitors, compositions and methods of use thereof
US11390623B2 (en) 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
KR20210033504A (ko) Magl 억제제로서 헤테로환형 스피로 화합물
TWI675826B (zh) 環狀經取代之咪唑并[4,5-c]喹啉衍生物
EP3810593A1 (en) Oga inhibitor compounds
HK40014240B (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
HK40014240A (en) Heteroarylphenoxy benzamide kappa opioid ligands
CA3045242C (en) Heteroarylphenoxy benzamide kappa opioid ligands
US20070197609A1 (en) Salts of inducible nitric oxide synthase dimerization inhibitors
HK40000923B (en) Compounds as dopamine d3 ligands
HK40000923A (en) 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
HK1228287B (en) Quinazoline derivatives as tam family kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014240

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant